# Study of Telitacicept in Generalized Myasthenia Gravis

> **NCT05737160** · PHASE3 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 114 (actual)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **BIOLOGICAL:** Telitacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05737160
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2024-11-26
- **Final completion:** 2024-12-12
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737160, "Study of Telitacicept in Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05737160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*